Literature DB >> 19729434

Mouse models of diabetic nephropathy.

Frank C Brosius1, Charles E Alpers, Erwin P Bottinger, Matthew D Breyer, Thomas M Coffman, Susan B Gurley, Raymond C Harris, Masao Kakoki, Matthias Kretzler, Edward H Leiter, Moshe Levi, Richard A McIndoe, Kumar Sharma, Oliver Smithies, Katalin Susztak, Nobuyuki Takahashi, Takamune Takahashi.   

Abstract

Diabetic nephropathy is a major cause of ESRD worldwide. Despite its prevalence, a lack of reliable animal models that mimic human disease has delayed the identification of specific factors that cause or predict diabetic nephropathy. The Animal Models of Diabetic Complications Consortium (AMDCC) was created in 2001 by the National Institutes of Health to develop and characterize models of diabetic nephropathy and other complications. This interim report and our online supplement detail the progress made toward that goal, specifically in the development and testing of murine models. Updates are provided on validation criteria for early and advanced diabetic nephropathy, phenotyping methods, the effect of background strain on nephropathy, current best models of diabetic nephropathy, negative models, and views of future directions. AMDCC investigators and other investigators in the field have yet to validate a complete murine model of human diabetic kidney disease. Nonetheless, the critical analysis of existing murine models substantially enhances our understanding of this disease process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729434      PMCID: PMC4075053          DOI: 10.1681/ASN.2009070721

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  68 in total

Review 1.  Role of macrophages in complications of type 2 diabetes.

Authors:  G H Tesch
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-10       Impact factor: 2.557

2.  Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.

Authors:  Berend Isermann; Ilya A Vinnikov; Thati Madhusudhan; Stefanie Herzog; Muhammed Kashif; Janusch Blautzik; Marcus A F Corat; Martin Zeier; Erwin Blessing; Jun Oh; Bruce Gerlitz; David T Berg; Brian W Grinnell; Triantafyllos Chavakis; Charles T Esmon; Hartmut Weiler; Angelika Bierhaus; Peter P Nawroth
Journal:  Nat Med       Date:  2007-11-04       Impact factor: 53.440

3.  Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy.

Authors:  Yan Tan; Joo-Seob Keum; Bing Wang; M Brent McHenry; Stuart R Lipsitz; Ayad A Jaffa
Journal:  Am J Physiol Renal Physiol       Date:  2007-06-27

4.  ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats.

Authors:  Julien Allard; Marie Buléon; Eric Cellier; Isabelle Renaud; Christiane Pecher; Françoise Praddaude; Marc Conti; Ivan Tack; Jean-Pierre Girolami
Journal:  Am J Physiol Renal Physiol       Date:  2007-06-27

5.  Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model.

Authors:  Marie Buléon; Julien Allard; Acil Jaafar; Françoise Praddaude; Zara Dickson; Marie-Thérèse Ranera; Christiane Pecher; Jean-Pierre Girolami; Ivan Tack
Journal:  Am J Physiol Renal Physiol       Date:  2008-03-26

6.  Decorin deficiency enhances progressive nephropathy in diabetic mice.

Authors:  Kevin Jon Williams; Gang Qiu; Hitomi Katoaka Usui; Stephen R Dunn; Peter McCue; Erwin Bottinger; Renato V Iozzo; Kumar Sharma
Journal:  Am J Pathol       Date:  2007-09-20       Impact factor: 4.307

7.  Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy.

Authors:  Intissar Ezzidi; Nabil Mtiraoui; Manel Ben Hadj Mohamed; Touhami Mahjoub; Maha Kacem; Wassim Y Almawi
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

8.  Diabetic eNOS knockout mice develop distinct macro- and microvascular complications.

Authors:  Sumathy Mohan; Robert L Reddick; Nicolas Musi; Diane A Horn; Bo Yan; Thomas J Prihoda; Mohan Natarajan; Sherry L Abboud-Werner
Journal:  Lab Invest       Date:  2008-04-07       Impact factor: 5.662

Review 9.  The kallikrein-kinin system in health and in diseases of the kidney.

Authors:  Masao Kakoki; Oliver Smithies
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

10.  Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.

Authors:  Celine C Berthier; Hongyu Zhang; MaryLee Schin; Anna Henger; Robert G Nelson; Berne Yee; Anissa Boucherot; Matthias A Neusser; Clemens D Cohen; Christin Carter-Su; Lawrence S Argetsinger; Maria P Rastaldi; Frank C Brosius; Matthias Kretzler
Journal:  Diabetes       Date:  2008-11-18       Impact factor: 9.461

View more
  263 in total

1.  Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.

Authors:  Andrew Advani; Qingling Huang; Kerri Thai; Suzanne L Advani; Kathryn E White; Darren J Kelly; Darren A Yuen; Kim A Connelly; Philip A Marsden; Richard E Gilbert
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

3.  A susceptibility gene for kidney disease in an obese mouse model of type II diabetes maps to chromosome 8.

Authors:  Streamson Chua; Yifu Li; Shun Mei Liu; Ruijie Liu; Ka Tak Chan; Jeremiah Martino; Zongyu Zheng; Katalin Susztak; Vivette D D'Agati; Ali G Gharavi
Journal:  Kidney Int       Date:  2010-06-02       Impact factor: 10.612

4.  Nicotine, smoking, podocytes, and diabetic nephropathy.

Authors:  Edgar A Jaimes; Ming-Sheng Zhou; Mohammed Siddiqui; Gabriel Rezonzew; Runxia Tian; Surya V Seshan; Alecia N Muwonge; Nicholas J Wong; Evren U Azeloglu; Alessia Fornoni; Sandra Merscher; Leopoldo Raij
Journal:  Am J Physiol Renal Physiol       Date:  2021-01-18

5.  Animal models of regression/progression of kidney disease.

Authors:  Beom Jin Lim; Hai-Chun Yang; Agnes B Fogo
Journal:  Drug Discov Today Dis Models       Date:  2014

6.  Decreased secretion and profibrotic activity of tubular exosomes in diabetic kidney disease.

Authors:  Jin Wen; Zhengwei Ma; Man J Livingston; Wei Zhang; Yanggang Yuan; Chunyuan Guo; Yutao Liu; Ping Fu; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-27

7.  The hyperglycemic and hyperinsulinemic combo gives you diabetic kidney disease immediately. Focus on "Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney".

Authors:  Seung Hyeok Han; Katalin Susztak
Journal:  Am J Physiol Cell Physiol       Date:  2013-12-11       Impact factor: 4.249

8.  Cannabinoid receptor 1 is a major mediator of renal fibrosis.

Authors:  Lola Lecru; Christophe Desterke; Stanislas Grassin-Delyle; Christos Chatziantoniou; Sophie Vandermeersch; Aurore Devocelle; Amelia Vernochet; Ninoslav Ivanovski; Catherine Ledent; Sophie Ferlicot; Meriem Dalia; Myriam Saïd; Séverine Beaudreuil; Bernard Charpentier; Aimé Vazquez; Julien Giron-Michel; Bruno Azzarone; Antoine Durrbach; Hélène François
Journal:  Kidney Int       Date:  2015-03-11       Impact factor: 10.612

9.  Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.

Authors:  Weier Qi; Hillary A Keenan; Qian Li; Atsushi Ishikado; Aimo Kannt; Thorsten Sadowski; Mark A Yorek; I-Hsien Wu; Samuel Lockhart; Lawrence J Coppey; Anja Pfenninger; Chong Wee Liew; Guifen Qiang; Alison M Burkart; Stephanie Hastings; David Pober; Christopher Cahill; Monika A Niewczas; William J Israelsen; Liane Tinsley; Isaac E Stillman; Peter S Amenta; Edward P Feener; Matthew G Vander Heiden; Robert C Stanton; George L King
Journal:  Nat Med       Date:  2017-04-24       Impact factor: 53.440

10.  Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications.

Authors:  Kelli M Sas; Pradeep Kayampilly; Jaeman Byun; Viji Nair; Lucy M Hinder; Junguk Hur; Hongyu Zhang; Chengmao Lin; Nathan R Qi; George Michailidis; Per-Henrik Groop; Robert G Nelson; Manjula Darshi; Kumar Sharma; Jeffrey R Schelling; John R Sedor; Rodica Pop-Busui; Joel M Weinberg; Scott A Soleimanpour; Steven F Abcouwer; Thomas W Gardner; Charles F Burant; Eva L Feldman; Matthias Kretzler; Frank C Brosius; Subramaniam Pennathur
Journal:  JCI Insight       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.